| Literature DB >> 25952647 |
Shintaro Takeuchi1, Muhammad Baghdadi2, Takahiro Tsuchikawa3, Haruka Wada2, Toru Nakamura3, Hirotake Abe1, Sayaka Nakanishi2, Yuu Usui2, Kohtaro Higuchi2, Mizuna Takahashi3, Kazuho Inoko3, Syoki Sato3, Hironobu Takano3, Toshiaki Shichinohe3, Ken-ichiro Seino4, Satoshi Hirano5.
Abstract
Pancreatic ductal adenocarcinoma (PDAC) is the most common type of pancreatic malignancies. PDAC builds a tumor microenvironment that plays critical roles in tumor progression and metastasis. However, the relationship between chemotherapy and modulation of PDAC-induced tumor microenvironment remains poorly understood. In this study, we report a role of chemotherapy-derived inflammatory response in the enrichment of PDAC microenvironment with immunosuppressive myeloid cells. Granulocyte macrophage colony-stimulating factor (GM-CSF) is a major cytokine associated with oncogenic KRAS in PDAC cells. GM-CSF production was significantly enhanced in various PDAC cell lines or PDAC tumor tissues from patients after treatment with chemotherapy, which induced the differentiation of monocytes into myeloid-derived suppressor cells (MDSC). Furthermore, blockade of GM-CSF with monoclonal antibodies helped to restore T-cell proliferation when cocultured with monocytes stimulated with tumor supernatants. GM-CSF expression was also observed in primary tumors and correlated with poor prognosis in PDAC patients. Together, these results describe a role of GM-CSF in the modification of chemotherapy-treated PDAC microenvironment and suggest that the targeting of GM-CSF may benefit PDAC patients' refractory to current anticancer regimens by defeating MDSC-mediated immune escape. ©2015 American Association for Cancer Research.Entities:
Mesh:
Substances:
Year: 2015 PMID: 25952647 DOI: 10.1158/0008-5472.CAN-14-2921
Source DB: PubMed Journal: Cancer Res ISSN: 0008-5472 Impact factor: 12.701